Overview

A Phase 1 Study of ARN-6039

Status:
Completed
Trial end date:
2017-02-01
Target enrollment:
Participant gender:
Summary
This Phase 1 study intends to determine the safety and tolerability of ARN-6039 in healthy subjects.
Phase:
Phase 1
Details
Lead Sponsor:
Arrien Pharmaceuticals
Collaborator:
Worldwide Clinical Trials